MedTrace Logo

An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)

NCT03972501 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-01-25

Study results available
· View outcomes & findings →

Summary

SOVS2019-070 is a single-center study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD).

Conditions

  • Meibomian Gland Dysfunction (MGD)
  • Contact Lens Discomfort (CLD)

Interventions

DRUG

AZR-MD-001 Vehicle

AZR-MD-001 is an ophthalmic ointment

DRUG

AZR-MD-001 Active Dose

AZR-MD-001 is an ophthalmic ointment

Sponsors & Collaborators

  • The University of New South Wales

    collaborator OTHER

  • Azura Ophthalmics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-04
Primary Completion
2020-12-11
Completion
2020-12-11

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03972501 on ClinicalTrials.gov